Orchid Pharma Limited (IN:ORCHPHARMA)
:ORCHPHARMA
Want to see IN:ORCHPHARMA full AI Analyst Report?
Top Page
Orchid Pharma Limited
(ORCHPHARMA)
Select Model
Select Model
Rating:55Neutral
Price Target:
₹1,070.00
▲(34.61% Upside)
Action:Reiterated
Date:06/17/26
The score is weighed down primarily by weak and inconsistent cash generation and a very expensive valuation (high P/E). These negatives are partly offset by a stronger balance sheet and solid technical momentum, though the stock’s extremely overbought readings add near-term risk.
Positive Factors
Manufacturing & R&D capabilities
Orchid’s integrated manufacturing and R&D footprint supports end-to-end generic product development and regulatory filings. That vertical capability helps sustain product pipeline replenishment, cost control, and entry into new markets, providing a durable operational advantage over distributors-only peers.
Negative Factors
Inconsistent cash generation / negative FCF
Cash conversion is uneven and free cash flow has been negative in multiple recent years, including a large FY2026 outflow. Persistent FCF volatility constrains financial flexibility, limits self-funded growth or deleveraging, and raises dependence on external financing for capex and working capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Manufacturing & R&D capabilities
Orchid’s integrated manufacturing and R&D footprint supports end-to-end generic product development and regulatory filings. That vertical capability helps sustain product pipeline replenishment, cost control, and entry into new markets, providing a durable operational advantage over distributors-only peers.
Read all positive factors
Orchid Pharma Limited (ORCHPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹48.84B
Dividend YieldN/A
Average Volume (3M)10.21K
Price to Earnings (P/E)239.7
Beta (1Y)1.25
Revenue Growth-12.00%
EPS Growth-79.57%
CountryIN
Employees871
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)10.31
Shares Outstanding50,719,105
10 Day Avg. Volume2,303
30 Day Avg. Volume10,213
Financial Highlights & Ratios
PEG Ratio-1.50
Price to Book (P/B)1.90
Price to Sales (P/S)3.02
P/FCF Ratio-8.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)18
Revenue Forecast (FY)₹15.13B
Orchid Pharma Limited Business Overview & Revenue Model
Company Description
Operating primarily within India, Orchid Pharma Limited is a pharmaceutical firm specializing in the creation, production, and commercialization of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), and nutraceutical products....
How the Company Makes Money
null...
Orchid Pharma Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
72
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.21B | 8.11B | 9.22B | 8.19B | 6.66B | 5.60B |
| Gross Profit | 3.27B | 1.59B | 3.55B | 1.36B | 706.89M | 2.32B |
| EBITDA | 1.02B | 411.28M | 1.45B | 1.42B | 1.43B | 621.38M |
| Net Income | 522.57M | 205.47M | 996.57M | 921.66M | 463.18M | -19.51M |
Balance Sheet | ||||||
| Total Assets | 17.22B | 19.11B | 16.88B | 15.54B | 12.25B | 11.11B |
| Cash, Cash Equivalents and Short-Term Investments | 1.50B | 840.74M | 1.83B | 45.24M | 275.21M | 48.27M |
| Total Debt | 2.82B | 3.63B | 1.75B | 1.35B | 3.31B | 2.68B |
| Total Liabilities | 4.48B | 6.23B | 4.21B | 3.84B | 5.37B | 4.63B |
| Stockholders Equity | 12.74B | 12.88B | 12.67B | 11.69B | 6.89B | 6.47B |
Cash Flow | ||||||
| Free Cash Flow | -1.47B | -2.74B | -1.31B | 611.77M | -665.75M | 780.71M |
| Operating Cash Flow | 115.10M | 1.10B | 192.15M | 1.26B | 183.38M | 924.75M |
| Investing Cash Flow | -906.39M | -2.96B | -269.31M | -3.12B | -312.14M | 1.13B |
| Financing Cash Flow | 1.00B | 1.72B | 252.22M | 1.67B | 311.66M | -2.17B |
Orchid Pharma Limited Technical Analysis
Positive
794.90
Price Trends
753.92
Positive
674.01
Positive
720.67
Positive
Market Momentum
70.97
Positive
64.83
Neutral
49.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ORCHPHARMA, the sentiment is Positive. The current price of 794.9 is below the 20-day moving average (MA) of 907.97, above the 50-day MA of 753.92, and above the 200-day MA of 720.67, indicating a bullish trend. The MACD of 70.97 indicates Positive momentum. The RSI at 64.83 is Neutral, neither overbought nor oversold. The STOCH value of 49.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ORCHPHARMA.
Orchid Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹52.10B | 40.51 | ― | 0.28% | 14.50% | 52.46% | |
67 Neutral | ₹39.22B | 28.49 | ― | 0.97% | 11.54% | 36.15% | |
59 Neutral | ₹30.44B | 12.05 | ― | ― | 8.53% | 67.93% | |
57 Neutral | ₹36.12B | 56.04 | ― | 0.03% | 15.15% | -7.86% | |
55 Neutral | ₹48.84B | 239.65 | ― | ― | -12.00% | -79.57% | |
52 Neutral | ₹27.13B | -351.79 | ― | ― | 6.64% | -177.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ORCHPHARMA
Orchid Pharma Limited
962.95
249.50
34.97%
IN:BLISSGVS
Bliss Gvs Pharma Limited
492.50
335.25
213.19%
IN:GUFICBIO
Gufic Biosciences Limited
360.15
-3.55
-0.98%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
133.60
37.48
39.00%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
568.70
-69.05
-10.83%
IN:UNICHEMLAB
Unichem Laboratories Limited
432.40
-157.50
-26.70%
Orchid Pharma Limited Corporate Events
Orchid Pharma says NCLT dismisses DBS Bank lease rent claim with no impact on operations
Apr 11, 2026
Orchid Pharma has disclosed that the National Company Law Tribunal’s Chennai Bench has dismissed an application filed by DBS Bank, formerly Lakshmi Vilas Bank, seeking lease rent and insolvency resolution process costs for the period when th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.